文献速递炎症性肠病

成人溃疡性结肠炎在基于人群队列中的自然史:一项系统综述

Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-06-16

该系统综述通过检索MEDLINE至2016年3月31日,纳入17个基于人群的起始队列中的60项研究(共15316例成人溃疡性结肠炎患者),描述其长期病程与结局。多数患者呈轻中度病程,约10%-15%呈侵袭性病程,10年累积复发风险70%-80%,5年和10年结肠切除累积风险10%-15%,死亡率未增加但疾病负担与工作能力丧失较高。

要点

  • 左半结肠炎是最常见病变范围,10%-30%患者出现病变扩展。
  • 约50%患者需溃疡性结肠炎相关住院,5年再住院风险约50%。
  • 达到黏膜愈合与较低的结肠切除风险相关。

核心结论

  • 溃疡性结肠炎是一种随时间致残的疾病。
  • 需要前瞻性队列评估早期使用改善病情疗法及以免疫调节剂和生物制剂为目标的治疗策略的影响。
  • 还需要来自低发病率地区的长期研究。

研究设计与样本

  • 系统综述,检索MEDLINE至2016年3月31日,纳入17个基于人群的起始队列中的60项研究,共15316例成人溃疡性结肠炎患者。

主要发现

  • 左半结肠炎是最常见病变范围,10%-30%患者出现病变扩展。
  • 多数患者呈轻中度病程,诊断时活动度最高,随后在不同时期缓解或轻度活动;约10%-15%患者经历侵袭性病程,10年累积复发风险为70%-80%。
  • 近50%患者需要溃疡性结肠炎相关住院,5年再住院风险约为50%。
  • 5年和10年结肠切除累积风险为10%-15%;达到黏膜愈合与较低的结肠切除风险相关。
  • 约50%患者接受糖皮质激素,该比例随时间下降,同时免疫调节剂使用增至20%、抗肿瘤坏死因子使用增至5%-10%。

局限性

  • 需要前瞻性队列评估近期早期使用改善病情疗法及以免疫调节剂和生物制剂为目标的治疗策略的影响。
  • 还需要来自低发病率地区的长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A comprehensive knowledge of the natural history of ulcerative colitis (UC) helps understand disease evolution, identify poor prognostic markers and impact of treatment strategies, and facilitates shared decision-making. We systematically reviewed the natural history of UC in adult population-based cohort studies with long-term follow-up. METHODS: Through a systematic literature review of MEDLINE through March 31, 2016, we identified 60 studies performed in 17 population-based inception cohorts reporting the long-term course and outcomes of adult-onset UC (n = 15,316 UC patients). RESULTS: Left-sided colitis is the most frequent location, and disease extension is observed in 10%-30% of patients. Majority of patients have a mild-moderate course, which is most active at diagnosis and then in varying periods of remission or mild activity; about 10%-15% of patients experience an aggressive course, and the cumulative risk of relapse is 70%-80% at 10 years. Almost 50% of patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ∼50%. The 5-year and 10-year cumulative risk of colectomy is 10%-15%; achieving mucosal healing is associated with lower risk of colectomy. About 50% of patients receive corticosteroids, although this proportion has decreased over time, with a corresponding increase in the use of immunomodulators (20%) and anti-tumor necrosis factor (5%-10%). Although UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability, comparable to Crohn's disease. CONCLUSIONS: UC is a disabling condition over time. Prospective cohorts are needed to evaluate the impact of recent strategies of early use of disease-modifying therapies and treat-to-target approach with immunomodulators and biologics. Long-term studies from low-incidence areas are also needed.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Fumery M, Singh S, Dulai PS, et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2017. PMID: 28625817. doi:10.1016/j.cgh.2017.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。